Diabetes Self-Management + CGM for Type 2 Diabetes

This trial explores whether combining a virtual diabetes self-management program, specifically The DECIDE Self-Management Program, with continuous glucose monitoring (CGM) can help adults with type 2 diabetes manage their condition more effectively. Participants will attend a 9-week online program and use CGM sensors to track blood sugar over 22 weeks. The trial aims to determine if this approach is practical and well-received by participants, potentially leading to better health outcomes. It suits those with type 2 diabetes who have high blood sugar levels and can use a smartphone. As an unphased trial, this study offers a unique opportunity to explore innovative diabetes management strategies that could enhance health and daily life.

Research has shown that continuous glucose monitoring (CGM) is generally safe for people with type 2 diabetes. Studies have found that CGM users often experience fewer low blood sugar episodes and achieve better blood sugar control. Additionally, CGM devices are typically easy to wear and continuously track blood sugar levels without frequent finger pricks.

The DECIDE Self-Management Program aims to help people with diabetes manage their condition more effectively. Although specific safety data is not available, the program focuses on teaching skills for problem-solving and improving self-care, which can lead to better overall health and increased confidence in managing diabetes.

The DECIDE Self-Management Program is unique because it combines a virtual education platform with continuous glucose monitoring (CGM) sensors, offering a comprehensive approach to managing Type 2 Diabetes. Unlike standard treatments that often rely solely on medication or periodic blood glucose checks, this program empowers patients with real-time data and personalized education, potentially improving their ability to manage their condition daily. Researchers are excited because the combination of these tools could lead to better patient engagement, improved glucose control, and a more personalized diabetes management experience.

In this trial, participants will receive both the DECIDE Self-Management Program and continuous glucose monitoring (CGM). Research has shown that CGM can significantly aid people with type 2 diabetes. One study found that those using CGM spent 26% more time with their blood sugar levels in a healthy range. Additionally, participants using CGM experienced a drop in their A1C levels, indicating better overall blood sugar control.